Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ticlopidine-induced cholestatic hepatitis. A case report]

P López1, A Castiella, L Bujanda

  • 1Servicio de Aparato Digestivo. Hospital Ntra. Sra. de Aránzazu, Universidad del País Vasco, San Sebastián.

Revista Espanola De Enfermedades Digestivas
|October 1, 1995
PubMed
Summary

Ticlopidine, an antiplatelet medication, can cause cholestatic hepatitis, a liver injury. Discontinuing ticlopidine led to normal liver function in this patient, highlighting the drug

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pancreatic cancer and biliary tract tumors in individuals with lynch syndrome.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025
Same author

Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2021
Same author

A Novel Noninvasive Method Based on Salivary Inflammatory Biomarkers for the Screening of Celiac Disease.

Cellular and molecular gastroenterology and hepatology·2021
Same author

Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer.

Scientific reports·2021
Same author

Pterostilbene modifies triglyceride metabolism in hepatic steatosis induced by high-fat high-fructose feeding: a comparison with its analog resveratrol.

Food & function·2021
Same author

Low Incidence of Advanced Neoplasia in Serrated Polyposis Syndrome After (Sub)total Colectomy: Results of a 5-Year International Prospective Cohort Study.

The American journal of gastroenterology·2019

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Drug-Induced Liver Injury

Background:

  • Ticlopidine is an antiplatelet agent used to prevent thrombotic events.
  • Drug-induced liver injury (DILI) is a significant concern in pharmacotherapy.
  • Cholestatic hepatitis is a pattern of liver damage characterized by impaired bile flow.

Observation:

  • A 74-year-old male developed cholestatic hepatitis after three months of ticlopidine therapy.
  • Exclusion of viral hepatitis, autoimmune liver disease, and biliary obstruction was confirmed.
  • Clinical presentation included elevated liver enzymes indicative of cholestasis.

Findings:

  • Cessation of ticlopidine resulted in normalization of liver tests within three months.
  • This case suggests a causal link between ticlopidine and cholestatic liver injury.

Related Experiment Videos

  • Review of literature identified similar cases associated with ticlopidine use.

    • Implications:

    • Clinicians should consider ticlopidine as a potential cause of cholestatic hepatitis.
    • Prompt drug withdrawal is crucial for managing ticlopidine-induced liver injury.
    • Further research into the mechanisms of ticlopidine hepatotoxicity is warranted.